✦ LIBER ✦

Recommendations for first-line antihypertensive drugs and combination therapies

✍ Scribed by Osamu Iimura

Book ID: 107540855
Publisher: Springer
Year: 2000
Tongue: English
Weight: 49 KB
Volume: 2
Category: Article
ISSN: 1522-6417
DOI: 10.1007/s11906-000-0019-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy as first-line treatm

Combination therapy as first-line treatment for hypertension

✍ Irene Gavras; Talma Rosenthal 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 310 KB

Combination therapy for prostate cancer.

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

✍ Fernand Labrie; Alain Belanger; Jacques Simard; Claude Labrie; André Dupont 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 965 KB

Combined therapies for cancer: a review

Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs

✍ Beata Zahorowska; Philip J. Crowe; Jia-Lin Yang 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 469 KB

Capecitabine in combination with Oxalipl

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer

✍ Yeon Hee Park; Jae-Lyun Lee; Baek-Yeol Ryoo; Min-Hee Ryu; Sung Hyun Yang; Bong S 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 274 KB

Combination therapy for rheumatoid arthr

Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus

✍ A. A. Borg; M. J. Davis; P. T. Dawes; M. F. Shadforth 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 263 KB

First-line therapy for chronic myeloid l

First-line therapy for chronic myeloid leukemia: Past, present, and future

✍ Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr